AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14744180
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Placebo and Active treatment)
Trial: 11412157
Drug: Ropivacaine combined
RxNorm normalized name: bupivacaine, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine combined with sufentanil 0.75 microg.ml‐1
Trial: 9646213
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily for four weeks plus amoxicillin 3 g daily during the first and second week (Group A)
Trial: 9646213
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily for 4 weeks plus placebo for two weeks (Group B)
Trial: 2885366
Drug: Clotiazepam 5
RxNorm normalized name: clotiazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotiazepam 5 mg
Trial: 2885366
Drug: Clotiazepam 10
RxNorm normalized name: clotiazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotiazepam 10 mg
Trial: 2885366
Drug: Clotiazepam 20
RxNorm normalized name: clotiazepam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotiazepam 20 mg
Trial: 30052729
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice of chemotherapy
Trial: 16687979
Drug: Tretin-X (0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretin-X (0.1% cream, 0.025% cream, 0.025% gel, 0.01% gel)
Trial: 16687979
Drug: Retin-A (0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retin-A (0.1% cream, 0.025% cream, 0.025% gel, 0.01% gel)
Trial: 8867397
Drug: Early nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early nutritional support (enteral or parenteral feeding) with appropriate caloric and protein requirement as soon as hemodynamic status was stabilized.
Trial: 8867397
Drug: Conventional method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional method with administration of hypo caloric intravenous regimen and supplement with oral diet as soon as bowel function returned.
Trial: 1363640
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil alone (500 mg)
Trial: 1363640
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil with food (500 mg)
Trial: 6377829
Drug: Glipizide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide (5 mg orally)
Trial: 6377829
Drug: Glipizide (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide (oral administration)
Trial: 20571433
Drug: venlafaxine‐XR 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: venlafaxine‐XR 225 mg/d
Trial: 20571433
Drug: mirtazapine 45
RxNorm normalized name: mirtazapine 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mirtazapine 45 mg/d
Trial: 16286163
Drug: Fasudil (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasudil (up to 80 mg three times daily)
Trial: 2323078
Drug: Lozenge containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lozenge containing 11 mg L-menthol
Trial: 499107
Drug: 2.5 ml
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 ml of 20% glucose per kg body weight (Group II)
Trial: 499107
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g chloropropamide (Group III)
Trial: 26781338
Drug: FospropofolFD 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FospropofolFD 20 mg/kg
Trial: 25079934
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g dose of cephalexin 30‐60 min before excision
Trial: 21507197
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg dipyrone (D15 group)
Trial: 21507197
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg dipyrone (D40 group)
Trial: 19730804
Drug: Asacol (400‐4800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asacol (400‐4800 mg single dose)
Trial: 19730804
Drug: Asacol (3600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asacol (3600 mg/day for 7 days)
Trial: 19730804
Drug: Asacol (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asacol (single and multiple doses)
Trial: 17312063
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of swirled mesentery and mushroom shape
Trial: 9934937
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily for up to 12 weeks
Trial: 2138972
Drug: Corrosion inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corrosion inhibitor component of cutting fluids
Trial: 730419
Drug: Org GC
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org GC 94 (45 mg/day for 14 days)
Trial: 20951543
Drug: Trauma Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma Management Therapy (TMT)
Trial: 26501533
Drug: naproxen +
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen + oxycodone/acetaminophen
Trial: 15606550
Drug: High-dose cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytotoxic treatment and autologous bone marrow transplantation
Trial: 10568870
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sucrose and nonnutritive sucking
Trial: 8738661
Drug: 1% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% amino acid dialysis solution (AA-P)
Trial: 8738661
Drug: 1.36% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.36% glucose dialysis solution (Glu-P)
Trial: 7035052
Drug: Antihistamine-adrenergic combination
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine-adrenergic combination
Trial: 31893580
Drug: APO(a)‐LRx 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APO(a)‐LRx 20 mg every 4 weeks
Trial: 31893580
Drug: APO(a)‐LRx 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APO(a)‐LRx 40 mg every 4 weeks
Trial: 31893580
Drug: APO(a)‐LRx 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APO(a)‐LRx 20 mg every 2 weeks
Trial: 31893580
Drug: APO(a)‐LRx 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APO(a)‐LRx 60 mg every 4 weeks
Trial: 31893580
Drug: APO(a)‐LRx 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APO(a)‐LRx 20 mg every week
Trial: 26842692
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen plus IV narcotics
Trial: 15818652
Drug: Ultrasound-guided local
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided local corticosteroid injections (G1 group)
Trial: 15818652
Drug: Standard local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard local corticosteroid injections without ultrasound guidance (G2 group)
Trial: 7697275
Drug: BA +
RxNorm normalized name: Ba
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BA + CS (combined beta 2‐agonist/corticosteroid therapy)
Trial: 7697275
Drug: BA +
RxNorm normalized name: Ba
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BA + AC (combined beta 2‐agonist/anticholinergic therapy)
Trial: 7697275
Drug: BA +
RxNorm normalized name: Ba
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BA + PL (beta 2‐agonist/placebo therapy)
Trial: 28374186
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (vD3) at various doses
Trial: 26564934
Drug: Self-administered CISS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered CISS
Trial: 26564934
Drug: Practitioner-administered CISS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practitioner-administered CISS
Trial: 19188545
Drug: Gemcitabine-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine-based chemotherapy
Trial: 21232139
Drug: Daily intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake of beef as a complementary food for 12 months
Trial: 21232139
Drug: Micronutrient fortified
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micronutrient fortified equi‐caloric rice‐soy cereal supplement for 12 months
Trial: 17709062
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (SH, n=10)
Trial: 11238476
Drug: Radioactive iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radioactive iodine (131I) therapy (4.44 MBq/g thyroid)
Trial: 11238476
Drug: Suppressive levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppressive levothyroxine treatment aiming at TSH values between 0.01 and 0.1 mU/L
Trial: 11238476
Drug: Suppressive levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppressive levothyroxine treatment
Trial: 3384075
Drug: Bambuterol 30
RxNorm normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bambuterol 30 mg once daily
Trial: 3384075
Drug: Terbutaline 5
RxNorm normalized name: terbutaline 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 5 mg sustained-release twice daily
Trial: 18319414
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE) 0.625 mg daily plus medroxyprogesterone acetate (MPA) 2.5 mg daily
Trial: 12741340
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of Sildenafil citrate (crushed and dissolved under the tongue) 15 minutes before planned sexual relations
Trial: 12741340
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Sildenafil citrate (50-100 mg) 30 minutes before planned sexual relations
Trial: 8618764
Drug: Pretreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment with one drop of diclofenac sodium 0.1% four times per day for 3 days before surgery plus one drop of diclofenac sodium 0.1% every 15 minutes for four doses, beginning 1 hour before surgery.
Trial: 8618764
Drug: No pretreatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pretreatment, but one drop of diclofenac sodium 0.1% every 15 minutes for four doses beginning 1 hour before surgery.
Trial: 6377118
Drug: Hexabrix 320
DrugBank: Ioxaglic acid (DB09313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hexabrix 320 mg I/ml
Trial: 24555511
Drug: Mentalization Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization Based Therapy for Eating Disorders (MBT-ED)
Trial: 26342674
Drug: Perioperative FOLFOX
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative FOLFOX chemotherapy
Trial: 20190349
Drug: Glucose solution
RxNorm normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solution (50 g glucose)
Trial: 20190349
Drug: Griffin's Fruitli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griffin's Fruitli bar (50 g available carbohydrate)
Trial: 20190349
Drug: Peak Fuel's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak Fuel's Summit bar (50 g available carbohydrate)
Trial: 18059578
Drug: Pre-test carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-test carbohydrate ingestion (CHO, 2x300 mL, 7% solution)
Trial: 15012171
Drug: Pioglitazone 7.5/15/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 7.5/15/30 mg/day or 15/30/45 mg/day
Trial: 15012171
Drug: Pioglitazone added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone added to metformin
Trial: 15012171
Drug: Pioglitazone added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone added to insulin
Trial: 15012171
Drug: Pioglitazone combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone combined with metformin
Trial: 15012171
Drug: Pioglitazone combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone combined with insulin
Trial: 11666121
Drug: TTFCA 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTFCA 60 mg thrice daily for 2 days before the flight, the day of the flight, and for another day after the flight
Trial: 11666121
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no drug or other treatment)
Trial: 9733274
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) with intravenous diamorphine
Trial: 9733274
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) with intravenous diamorphine
Trial: 31568288
Drug: Large-gel-particle hyaluronic
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large-gel-particle hyaluronic acid with 0.3% lidocaine, 20 mg/ml
Trial: 26818364
Drug: 30% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% sucrose solution
Trial: 20712499
Drug: Internet-based self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based self-administered program
Trial: 12476093
Drug: Verteporfin therapy
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin therapy (6 mg/m² body surface area)
Trial: 12476093
Drug: Verteporfin therapy
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin therapy (6 to 20 mg/m²)
Trial: 10423707
Drug: 20-30 mmol/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-30 mmol/day of oral magnesium hydroxide
Trial: 2655687
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of both agents
Trial: 2252453
Drug: Physostigmine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine treatment
Trial: 6773843
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (1.2 g/day)
Trial: 31065881
Drug: Daily partner‐focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily partner‐focused petitionary prayer (PFPP)
Trial: 25714044
Drug: Gardasil (qHPV)
DrugBank: Human papillomavirus type 18 L1 capsid protein antigen (DB10302)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gardasil (qHPV) booster dose
Trial: 25714044
Drug: Cervarix (bHPV)
RxNorm normalized name: human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine Prefilled Syringe [Cervarix]
DrugBank: Human papillomavirus type 18 L1 capsid protein residues 2-472 antigen (DB10995)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervarix (bHPV) booster dose
Trial: 25406682
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with house-dust mite or grass pollen; applied for 2 years after a dose-up phase.
Trial: 25406682
Drug: Placebo; applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; applied for 2 years after a dose-up phase.
Trial: 22337568
Drug: Etoricoxib 120
RxNorm normalized name: etoricoxib 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 120 mg preoperatively
Trial: 14734464
Drug: Imatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib treatment (median duration of 13 months)
Trial: 11964590
Drug: Morphine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.05 mg/kg bolus + 0.2 mg/kg infusion over 40 min)
Trial: 11964590
Drug: Lidocaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1 mg/kg bolus + 4 mg/kg infusion)
Trial: 11964590
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo (Diphenhydramine 10 mg bolus + 40 mg infusion)
Trial: 9579445
Drug: dl-norgestrel (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl-norgestrel (0.05 mg/day)
Trial: 9579445
Drug: medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: medroxyprogesterone acetate (2.5 mg/day)
Trial: 2633927
Drug: Colchicine tablets
RxNorm normalized name: Colchicine Tablets
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine tablets (A)
Trial: 2633927
Drug: Colchicine oral
RxNorm normalized name: colchicine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine oral solution (B)
Trial: 7377746
Drug: Sulfadiazine (SD)
RxNorm normalized name: Sulfadiazine
DrugBank: Sulfadiazine (DB00359)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfadiazine (SD) 4 mg/kg twice a day, loading dose 8 mg/kg
Trial: 7377746
Drug: Fulfafurazole (SF)
RxNorm normalized name: sulfafurazole
DrugBank: Sulfisoxazole (DB00263)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fulfafurazole (SF) 50 mg/kg four times a day
Trial: 30945088
Drug: Liberal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal fluid strategy (12 ml/kg/h)
Trial: 30945088
Drug: Restricted fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted fluid strategy (4 ml/kg/h)
Trial: 25829263
Drug: Educational booklet
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational booklet on anticoagulant treatment with warfarin
Trial: 23661293
Drug: Concurrent oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concurrent oxaliplatin 70 mg/m² weekly for six cycles
Trial: 10989730
Drug: diltiazem 300
RxNorm normalized name: diltiazem 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem 300 mg/daily
Trial: 10989730
Drug: amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine 10 mg/daily
Trial: 1285740
Drug: Adjuvant cisplatin-based
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant cisplatin-based chemotherapy (n = 97)
Trial: 1285740
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for recurrent disease (n = 83)
Trial: 1285740
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment group (control group)
Trial: 1285740
Drug: Both chemotherapy
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both chemotherapy groups (adjuvant and recurrent)
Trial: 3934402
Drug: 2.2 g
RxNorm normalized name: Vaporizer Safeguard 2.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.2 g protein/kg/day
Trial: 3934402
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g protein/kg/day
Trial: 20812862
Drug: Pentaerythritol tetranitrate
RxNorm normalized name: Pentaerythritol tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentaerythritol tetranitrate (PETN) 80 mg orally two times per day for 14 days
Trial: 20812862
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 40 mg retarded release orally two times per day for 14 days
Trial: 16981945
Drug: Topical misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical misoprostol
Trial: 27086023
Drug: Ongoing PRN
RxNorm normalized name: Ongo-Fin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing PRN ranibizumab monotherapy (n = 119)
Trial: 23227680
Drug: Meridian cosmetology
RxNorm normalized name: sibutramine hydrochloride Oral Capsule [Meridia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meridian cosmetology treatment (including acupuncture at specific body acupoints and local needling therapy)
Trial: 23227680
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (oral administration of Vitamin C and E for 3 months)
Trial: 23227680
Drug: Meridian cosmetology
RxNorm normalized name: sibutramine hydrochloride Oral Capsule [Meridia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meridian cosmetology treatment